Genome Mapping Application in Diagnosis and Treatment of different Cancers
DOI:
https://doi.org/10.61841/ja4xzk77Keywords:
Genome Mapping, Diagnosis and Treatment, Global HealthcareAbstract
A wide range of cancer risk factors acts as mutagens and contributes to mutations in human body cells, some might cause carcinogenesis in cells, and then lead to the development of malignancies. Mutations occur in different cancers that can be in various forms, for instance, some contain gene amplification, but some have gene deletion. Doctors always seek to identify those essential genetic mutations in cancers for diagnosis and treatment, but those mutations increase as cancer cells develop over time, for example, metastasizing from primary sites to secondary sites. Genome mapping on cancers via different techniques are developed to be used as indicators of mutated genes, cancer genomes, therefore, provide new data for diagnosis and treatments of this disease, which assists pharmaceutical advancing on targeted therapy for treating specifically on gene mutations. Although genome mapping is helpful, there are ethical issues appear as well, which genome information can be considered as personal privacies. This review introduces mutation types in cancer as well as cancer risk factors, and how some of those mutations can be diagnosed by genome mapping, which focuses particularly on three methods in terms of their principles and how some of those are applied to diagnosis and drug development on four types of cancer.
Downloads
References
[1] Ali Moustafa Elkhateeb, Y. (2017). Impacts of speedy meals relating to Free Radicals and Antioxidants.
American Journal of Laboratory remedy, [online] 2(6), p.156.
[2] AMBOSS. (2019). Chemotherapeutic operators – talents for medicinal understudies and medical
professionals. [online] to be had at: https://www.Amboss.Com/us/information/Chemotherapeutic_agents
[Accessed 20 Jul. 2019].
[3] Armstrong, B. What's more, Kricker, A. (2001). The study of sickness transmission of UV precipitated
epidermis malignant progress. Diary of Photochemistry and Photobiology B: Biology, [online] 63(1-three),
pp. Eight-18.
[4] Arriola, E., Marchio, C., Tan, D., Drury, S., Lambros, M., Natrajan, R., Rodriguez-Pinilla, S., Mackay, A.,
Tamber, N., Fenwick, k., Jones, C., Dowsett, M., Ashworth, A. What's more, Reis-Filho, J. (2008).
Genomic investigation of the HER2/TOP2A amplicon in bosom malignancy and bosom disorder cell
traces. Research facility Investigation, [online] 88(5), pp.491-503.
[5] Bagci, O. What's more, Kurtgöz, S. (2015). Intensification of phone oncogenes in strong tumors. North
American Journal of clinical Sciences, [online] 7(eight), p.341.
[6] Balko, J., Stricker, T. Also, Arteaga, C. (2013). The genomic consultant of bosom malignant development:
which streets lead to higher taken with treatments? Bosom melanoma study, [online] 15(four). Available at:
https://www.Ncbi.Nlm.Nih.Gov/pubmed/23905624 [Accessed 28 Jul. 2019].
[7] Baptista, P. (1995). Access NCBI by means of the arena huge internet (WWW). Atomic Biotechnology,
[online] 3(1), pp. Seventy five - seventy five.
[8] Bussemakers, M., van Bokhoven, A., Verhaegh, G., Smit, F., Karthaus, H., Schalken, J., Debruyne, F., Ru,
N. Also, Isaacs, W. (1999). DD3: a brand new Prostate-express Gene, particularly Overexpressed in
Prostate melanoma. Malignant growth study. [online] available at: https://cancerres.Aacrjournals.Org/
content material/fifty nine/23/5975 [Accessed 10 Aug. 2019].
[9] Ailment. (2019). Key statistics for Pancreatic melanoma. [online] available at: https://www.Cancer.Org/
malignant progress/pancreatic-sickness/about/key-records.Html [Accessed 28 Jul. 2019].
[10] Cancer.Internet. (2019). Pancreatic cancer - records. [online] on hand at: https://www.Cancer.Net/disorder
types/pancreatic-malignant growth/insights [Accessed 2 Aug. 2019].
[11] Cancer.Net. (2019). The link between weight problems and cancer. [online] to be had at:
https://www.Cancer.Web/exploring ailment care/recordings/after-cure-and-survivorship/interface amongst
heftiness and-malignant development [Accessed 3 Jul. 2019].
[12] Champaneria, M., Modlin, I., Kidd, M. Also, Eick, G. (2006). Friedrich Feyrter: A precise mind in a
Diffuse procedure. Neuroendocrinology, [online] eighty three(5-6), pp. 394-404.
[13] Clark, J., Edwards, S., Feber, A., Flohr, P., John, M., Giddings, I., Crossland, S., Stratton, M., Wooster, R.,
Campbell, C. Additionally, Cooper, C. (2003). Genome-huge screening for whole hereditary misfortune in
prostate malignant development via near hybridization onto cDNA microarrays. Oncogene, [online] 22(8),
pp. 1247-1252.
[14] Eurostat. (2019). World cancer Day: 1 out of 4 passings precipitated via malignant progress in the eu.
[online] to be had at: https://ec.Europa.European/eurostat/net/items eurostat-news/ -/EDN-20170203-1
[Accessed 2 Jul. 2019].
[15] Development. (2019). Transformations. [online] on hand at: https://year10sciencewebsite.Weebly.Com/
mutations.Html [Accessed 2 Aug. 2019].
[16] Hereditary features residence Reference. (2019a). What are entire exome sequencing and entire genome
sequencing? [online] to be had at: https://ghr.Nlm.Nih.Gov/preliminary/checking out/sequencing [Accessed
2 Aug. 2019].
[17] Hereditary characteristics home Reference. (2019b). What's a high-quality transformation and how do
alterations occur? [online] to be had at: https://ghr.Nlm.Nih.Gov/groundwork/ mutations and
disorders/genemutation [Accessed 18 Jul. 2019].
[18] Goddard, k., Weinmann, S., Richert-Boe, k., Chen, C., Bulkley, J. In addition, Wax, C. (2012).
HER2 evaluation and Its impact on Breast cancer remedy choices. Normal wellness Genomics,
[online] 15(1), pp.1-10.
[19] Griffiths, A., Miller, J., Suzuki, D. Moreover, Lewontin, R. (2000). A prologue to hereditary investigation.
Seventh ed. New york, new york: Freeman.
[20] Han, J., Lee, Y., Kim, B., Lee, G., Lee, S., Kim, E., Kim, H. Furthermore, Bhak, J. (2014). Whole genome
investigation of a patient with opening time little mobile lung malignancy. The Pharmacogenomics
Journal, [online] 14(6), pp.503-508.
[21] Harvard health. (2017). Squamous telephone Carcinoma of the Lung - Harvard health. [online] on hand at:
https://www.Health.Harvard.Edu/a_to_z/squamous-telephone-carcinoma-of-the-lung a to z [Accessed 28
Jul. 2019].
[22] Holderfield, M. (2017). Endeavors to increase KRAS Inhibitors. Bloodless Spring Harbor perspectives in
treatment, [online] eight(7), p.A031864. Available at: http://perspectivesinmedicine.Cshlp.Org/content
material/8/7/a031864 [Accessed 2 Aug. 2019].
[23] Huang, W., Hsu, S., Huang, H., solar, Y., Chou, C., Weng, S. Furthermore, Huang, H. (2014). MethHC: a
database of DNA methylation and satisfactory articulation in human malignant progress. Nucleic Acids
study, [online] forty three (D1), pp. D856-D861.
[24] Ishkanian, A., Mallof, C., Ho, J., Meng, An., Albert, M., Syed, A., van der Kwast, T., Milosevic, M.,
Yoshimoto, M., Squire, J., Lam, W. Additionally, Bristow, R. (2009). Excessive-objectives showcase CGH
acknowledges novel areas of genomic exchange in core hazard prostate malignancy. The Prostate, [online]
69(10), pp. 1091-1100.
[25] Jones, S., Anagnostou, V., Lytle, ok., Parpart-Li, S., Nesselbush, M., Riley, D., Shukla, M., Chesnick, B.,
Kadan, M., Papp, E., Galens, okay., Murphy, D., Zhang, T., Kann, L., Sausen, M., Angiuoli, S., Diaz, L.
Also, Velculescu, V. (2015). Custom-made genomic examinations for malignancy transformation
disclosure and translation. Science Translational treatment, [online] 7(283), pp.283ra53-283ra53.
[26] Jones, S., Zhang, X., Parsons, D., Lin, J., Leary, R., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H.,
Jimeno, A., Hong, S., Fu, B., Lin, M., Calhoun, E., Kamiyama, M., Walter, ok., Nikolskaya, T., Nikolsky,
Y., Hartigan, J., Smith, D., Hidalgo, M., Leach, S., Klein, A., Jaffee, E., Goggins, M., Maitra, An.,
Iacobuzio-Donahue, C., Eshleman, J., Kern, S., Hruban, R., Karchin, R., Papadopoulos, N., Parmigiani, G.,
Vogelstein, B., Velculescu, V. Also, Kinzler, k. (2008). Middle Signaling Pathways in Human Pancreatic
Cancers published via global Genomic Analyses. Science, [online] 321(5897), pp.1801-1806.
[27] Joo, W., Visintin, I. Also, Mor, G. (2013). Directed malignancy remedy – Are the occasions of
predominant chemotherapy numbered?. Maturitas, [online] 76(four), pp.308-314.
[28] Kadota, M., Sato, M., Duncan, B., Ooshima, A., Yang, H., Diaz-Meyer, N., Gere, S., Kageyama, S.,
Fukuoka, J., Nagata, T., Tsukada, okay., Dunn, B., Wakefield, L. Also, Lee, M. (2009). Distinguishing
proof of Novel Gene Amplifications in Breast melanoma and Coexistence of Gene Amplification with an
Activating Mutation of PIK3CA. Malignancy research, [online] 69(18), pp.7357-7365.
[29] Kallioniemi, A., Kallioniemi, O., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H., Pinkel, D., grey, J.
Also, Waldman, F. (1994). Identification and mapping of more advantageous DNA successions in bosom
malignant development with the aid of relative genomic hybridization. Methods of the countrywide
Academy of Sciences, [online] ninety one(6), pp.2156-2160.
[30] Kimchi-Sarfaty, C., Oh, J., Kim, I., Sauna, Z., Calcagno, An., Ambudkar, S. Additionally, Gottesman, M.
(2007). A "Quiet" Polymorphism in the MDR1 Gene alterations Substrate Specificity. Science, [online]
315(5811), pp.525-528.
[31] Korde, L. Also, Gadalla, S. (2009). Malignancy hazard comparison for the primary Care surgeon. Principal
Care: Clinics in office practice, [online] 36(three), pp.471-488.
[32] Mader, S., Pendarvis, M. What's extra, Demott, S. (2007). McGraw Hill Biology. Ninth ed. Boston:
McGraw-Hill bigger education, p.209.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
